Mechanism-Based Drug Rejection? Ataluren’s Unlikely Personalized Medicine Milestone
Executive Summary
US FDA has shown it can be very flexible in expanding indications for a targeted therapy with a clearly established mechanism of action. But, as PTC Therapeutics learned, the agency’s willingness to apply mechanistic knowledge for targeted therapies cuts both ways.